Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Sep-30-22 | Sep-05-22 | Sep-30-21 | Sep-05-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 |
| | 10-K | 8-K | 10-K | 8-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Product Sales | 26.7 | | 24.7 | | 22.7 | 21.4 | 20.8 | 19.1 |
| Other | | | | | | 0.3 | 0.0 | 0.1 |
| Other | 0.9 | | 2.2 | | 0.8 | | | |
| In Vitro Diagnostics revenues | 27.6 | | 26.9 | | 23.5 | 21.7 | 20.8 | 19.1 |
| Revenue growth [+] | 2.5% | | 14.6% | | 8.0% | 4.3% | 8.9% | 5.3% |
| Product Sales | 8.1% | | 8.8% | | 6.2% | 2.9% | 9.1% | |
| Other | | | | | | 882.4% | -54.1% | |
| EBITDA | 13.4 | | 14.2 | | 12.3 | 11.1 | 9.0 | 8.7 |
| EBITDA margin | 48.7% | | 52.7% | | 52.2% | 51.0% | 43.3% | 45.5% |
| Depreciation and amortization | 0.4 | | 0.4 | | 0.5 | 0.5 | 0.4 | 0.4 |
| EBIT | 13.1 | | 13.8 | | 11.8 | 10.6 | 8.6 | 8.3 |
| EBIT margin | 47.4% | | 51.2% | | 50.2% | 48.9% | 41.4% | 43.4% |
| |
| Revenue Mix | 27.6% | | 25.6% | | 24.7% | 21.7% | 25.6% | 26.2% |
| EBIT Mix | | | 211.0% | | | 164.2% | | 116.8% |
|